Pamela Taxel is an Endocrinology/Metabolic physician affiliated with UConn Health. OpenAlex indexes 62 publications with 1,118 citations (h-index 18); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
55.9%Bisphosphonates40.8%Risedronate Sodium Dr58%Risedronate Sodium42%Part D≥19 patientsOther drugs affecting bone structure and mineralization9.5%Evenity (2 Syringes)100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
37.9%l-Thyroxine32.7%Levothyroxine Sodium54%Synthroid46%Part D<11 patientsParathyroid Hormone Analog5.2%Forteo100%Part D<11 patientsCardiovascular
6.2%Thiazide diuretic6.2%Hydrochlorothiazide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1997–2008 per NIH RePORTER. The latest:
- CLINICAL TRIAL: THE EFFECT OF RISEDRONATE ON BONE TURNOVER AND BONE MASS IN OLDE
University of Connecticut Sch of Med/dnt
FY2008$7,368M01RR006192 - EFFECTS OF ORAL ESTRADIOL THERAPY ON OSTEOCLASTOGENESIS
University of Connecticut Sch of Med/dnt
FY2008$1,842M01RR006192
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dental implant and bone augmentation treatment in bone-compromised patients: Oral health-related quality of life outcomes
Journal of Prosthetic Dentistry
2023 - PSAT222 Muscle Weakness, Bone Pain, and Stress Fractures: When a Fracture is NOT JUST a Fracture: A Case Report
Journal of the Endocrine Society
2022 - Development of Delayed Paraneoplastic ACTH Syndrome in Small Cell Lung Carcinoma
Journal of the Endocrine Society
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Martha Radford, MD
UConn Health
David Steffens, MD
UConn Health
Mark Metersky, MD
UConn Health
Carol Pilbeam, MD
UConn Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”